Viewing data from:

MUPIROCIN

ANDA

MUPIROCIN | A065085 | TEVA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Citizen Petitions

1 petition from Regulations.gov

Petition	Type	Filed	Status	Petitioner
Citizen Petition from GlaxoSmithKline FDA-2004-P-0537 · 10 docket documents GlaxoSmithKline filed this citizen petition under 21 CFR 10.30 requesting that the FDA Commissioner refrain from receiving, reviewing, and approving any Abbreviated New Drug Applications (ANDAs) for nasal mupirocin calcium products containing the amorphous form of the active pharmaceutical ingredien	505(q)	2008-05-28	Withdrawn	GlaxoSmithKline

Source: Regulations.gov. FDA citizen petitions matched by application number.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.1362

per gm

Lowest NADAC/Unit

$0.1362

per gm

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00093101042MUPIROCIN 2% OINTMENT	$0.1362	GM	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$7.76

Highest Price

$7.76

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00093-1010-42MUPIROCIN 2% OINT,TOP	$7.76	FSS	AvKare, LLC	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Mupirocin (2024)

Total Spending

$7.8M

Total Claims

63,159

Beneficiaries

42,665

Avg Cost/Unit

$4.22

Spending Trend

$32.1M(2019)→$22.0M(2020)→$21.6M(2021)→$17.9M(2022)→$12.1M(2023)→$7.8M(2024)

YoY Change:-37.6%

5yr CAGR:-19.5%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain11 active DMFs2 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVMUPIROCIN

DMF 140401999

TAPI NL BVMUPIROCIN

DMF 152872001

HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTDMUPIROCIN (NON-STERILE BULK FORM)

DMF 207672007

CONCORD BIOTECH LTDMUPIROCIN USP

DMF 286182014

SYNGEN BIOTECH CO LTDMUPIROCIN

DMF 302922016

KAWMAN PHARMAMUPIROCIN USP

DMF 322682017

FUZHOU CONTAY BIOTECHNOLOGY CO LTDMUPIROCIN

DMF 328242018

BILLS BIOTECH PVT LTDMUPIROCIN IP/BP/USP

DMF 333882018

FUJIAN COMHONY BIOTECHNOLOGY CO LTDMUPIROCIN

DMF 375102022

CHENGDU YACHT BIOTECHNOLOGY CO LTDMUPIROCIN

DMF 424532025

ENDOC BIOTECH PVT LTDMUPIROCIN USP

DMF 425712025

GLAXOSMITHKLINE LLCInactiveMUPIROCIN FREE ACID AND MUPIROCIN CALCIUM (NON-STERILE)

DMF 139611999

XELLIA PHARMACEUTICALS APSInactiveMUPIROCIN USP, NON-STERILE

DMF 238452010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 2%

0 patents0 exclusivities▴

OINTMENT;TOPICAL | Approved: Nov 7, 2003

No patent or exclusivity listings for this strength.